Management of challenging myelofibrosis after JAK inhibitor failure and/or progression-Reference-Cited by-同舟云学术

Management of challenging myelofibrosis after JAK inhibitor failure and/or progression

Published:2020-07 Issue: Volume:42 Page:100716
ISSN:0268-960X
Container-title:Blood Reviews
language:en
Short-container-title:Blood Reviews

Author:

Scherber Robyn M.,Mesa Ruben A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference80 articles.

1. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science;Kilpivaara;Leukemia.,2008

2. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors;Cerquozzi;Blood Cancer J,2015

3. A pooled overall survival analysis of the COMFORT studies: 2 randomized phase 3 trials of Ruxolitinib for the treatment of myelofibrosis;Hagop;BLood.,2013

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myelofibrosis and anemia: A German claims data analysis to describe epidemiology and current treatment;European Journal of Haematology;2024-08-05

2. Anterior Uveitis After Discontinuation of Janus Kinase Inhibitor, Ruxolitinib;Journal of Medical Cases;2024-08

3. MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients;Annals of Hematology;2024-07-29

4. Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM;Future Oncology;2024-07-29

5. Clinical assessment of momelotinib drug–drug interactions via CYP3A metabolism and transporters;Clinical and Translational Science;2024-04